TrialLancet (London, England)2024

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.

Magnus Ochoge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.